HIV infection-related tuberculosis: Clinical manifestations and treatment

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 3, 2010, Pages

  Sterling, Timothy R ^a   Pham, Paul A ^b   Chaisson, Richard E ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; COTRIMOXAZOLE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETHAMBUTOL; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; ISONIAZID; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; ZIDOVUDINE;

CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ANTAGONISM; EXTRAPYRAMIDAL SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER TOXICITY; PERIPHERAL NEUROPATHY; PREGNANCY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; TUBERCULOSIS;

EID: 77951798462     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651495     Document Type: Review

References (65)

1. Bassett I, Chetty S, Wang B, et al. Intensive TB screening for HIV-infected patients ready to start ART in Durban, South Africa: limitations of WHO guidelines. In: Program and abstracts of the 16th Con-ference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 779.
2. Edwards D, Vogt M, Bangani N, et al. Baseline screening for TB among patients enrolling in an ART service in South Africa. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 780.
3. Keiper MD, Beumont M, Elshami A, et al. CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. Chest 1995; 107:74-80.
4. Geng E, Kreiswirth B, Bruzynski J, Schluger NW. Clinical and radio-graphic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 2005; 293(22) :2740-2745. (Pubitemid 40965086)
5. Greenberg SD, Frager D, Suster B, Walker S, Stavropoulos C, Rothpearl A. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994; 193(1):115-119. (Pubitemid 24298009)
6. Perlman DC, El Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997; 25(2):242-246.
7. Pepper T, Joseph P, Mwenya C, et al. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory speci-men cultures. Int J Tuberc Lung Dis 2008; 12(4):397-403. (Pubitemid 351507252)
8. Samb B, Sow PS, Kony S, et al. Risk factors for negative sputum acidfast bacilli smears in pulmonary tuberculosis: results from Dakar, Senegal, a city with low HIV seroprevalence. Int J Tuberc Lung Dis 1999; 3(4):330-336.
9. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smearnegative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369(9578):2042-2049. (Pubitemid 46908825)
10. Chaisson RE, Schechter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136:570-574.
11. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 counts in patients with human immunodeficiency infection. Am Rev Respir Dis 1993; 148:1292-1297. (Pubitemid 2004673)
12. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167(4) :603-662.
13. World Health Organization. Global Tuberculosis Programme. Treat-ment of tuberculosis: guidelines for national programmes, 3rd ed. Ge-neva: World Health Organization, 2003.
14. Hopewell PC, Pa M, Maher D, Uplekar M, Raviglione MC. Inter-national Standards for tuberculosis care. Lancet Infect Dis 2006; 6(11): 710-725.
15. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-1191.
16. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Resp Crit Care Med 1996; 154:1034-1038. (Pubitemid 126679542)
17. Connolly C, Reid A, Davies G, Sturm W, McAdam KP, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999; 13:1543-1547. (Pubitemid 29396687)
18. El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998; 26:1148-1158.
19. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332:779-784.
20. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomized trial. Lancet 2000; 356:1470-1474.
21. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33(10):1762-1769. (Pubitemid 33044545)
22. Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly-observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin. Clin Infect Dis 2004; 38:731-736. (Pubitemid 38333871)
23. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175(11): 1199-1206. (Pubitemid 46855463)
24. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 2003; 17(14):2063-2070.
25. The Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360:528-534.
26. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, etham-butol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48(12): 1685-1694.
27. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112:407-1115
28. Chang KC, Leung CC, Yew WW, Ho SC, Tarn CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170(10):1124-1130. (Pubitemid 39488627)
29. Chang KC, Leung CC, Yew WW, Chan SL, Tarn CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174(10):1153-1158.
30. Nolan CM, Williams DL, Cave MD, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995; 152:1067-1071.
31. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of monorifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153(2):837-840. (Pubitemid 26051369)
32. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843-1847. 33. Burman W, Benator D, Vernon A, et al. Acquired rifamycin-resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173(3):350-356. (Pubitemid 29251017)
33. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40(10):1481-1491. (Pubitemid 40628637)
34. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662.
35. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Management of tuberculosis: a guide for low income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
36. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimeth-oprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353(9163): 1469-1475.
37. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687-1693. (Pubitemid 33124328)
38. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341:1174-1179. (Pubitemid 29480655)
39. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tu-berculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2000; 4:1026-1031.
40. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34(4):543-546. (Pubitemid 34112278)
41. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359(9323):2059-2064. (Pubitemid 34680968)
42. Girardi E, Sabin CA, D'Arminio MA, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral ther-apy in Europe and North America. Clin Infect Dis 2005; 41(12): 1772-1782. (Pubitemid 41759864)
43. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20(12):1605-1612. (Pubitemid 44162402)
44. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177(7):680-685. (Pubitemid 351490554)
45. Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199(3):437-444.
46. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45(11):1518-1521. (Pubitemid 351411886)
47. Pablos-Mendez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276:1223-1228. (Pubitemid 26337704)
48. Whalen C, Okwera A, Johnson J, et al. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration. Am J Resp Crit Care Med 1996; 153(6 Pt 1): 1977-1981.
49. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
50. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362(9377):22-29. (Pubitemid 36835816)
51. Leonard MK, Larsen N, Drechsler H, et al. Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. Clin Infect Dis 2002; 34(7):1002-1007.
52. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16(l):75-83. (Pubitemid 34062184)
53. Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17(18): 2615-2622. (Pubitemid 38402339)
54. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
55. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus. Am J Resp Crit Care Med 1998; 157:1871-1876. (Pubitemid 28311273)
56. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19(4):399-406. (Pubitemid 40446186)
57. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8(8):516-523. (Pubitemid 352005824)
58. Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196(Suppl 1): S46-S51. (Pubitemid 47206084)
59. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
60. Torok ME, Yen NTB, Chau TTH, et al. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). 2009. Abstract H-1224.
61. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44(2):229-234.
62. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis, http://www.cdc.gov/tb/publications/ guidelines/TB-HIV-Drugs/default.htm. Accessed 25 March 2010.
63. Boulle A, Van CG, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300(5):530-539.
64. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIVinfected patients receiving rifampicin: The N2R Study. Clin Infect Dis 2009; 48(12):1752-1759.
65. Brainerd DM, Petry AS, Fang L, et al. Lack of a clinically important effect of rifabutin on raltegravir pharmacokinetics. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). 2009. Abstract Al-1296.